上海医药(601607.SH)：前三季度净利润51.47亿元，同比增长26.96%

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 215.07 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 2.6% [1] - The net profit attributable to shareholders reached 5.15 billion yuan, marking a significant year-on-year increase of 26.96% [1] - The basic earnings per share stood at 1.39 yuan [1] Financial Performance - Total revenue for the first three quarters: 215.07 billion yuan, up 2.6% year-on-year [1] - Net profit attributable to shareholders: 5.15 billion yuan, up 26.96% year-on-year [1] - Basic earnings per share: 1.39 yuan [1]